| Target Validation Information | |||||
|---|---|---|---|---|---|
| Target ID | T92057 | ||||
| Target Name | Receptor protein-tyrosine kinase erbB-4 | ||||
| Target Type | Clinical Trial |
||||
| Drug Potency against Target | BMS-599626 | Drug Info | IC50 = 80 nM | [552652] | |
| CI-1033 | Drug Info | IC50 = 7 nM | |||
| Action against Disease Model | CI-1033 | The pan-ErbB inhibitor CI-1033 selectively inhibited growth of fulvestrant resistant cell lines. CI-1033 inhibited Erk but not Akt signaling, which as well as Erk is important for antiestrogen resistant cell growth | [552975] | Drug Info | |
| The Effect of Target Knockout, Knockdown or Genetic Variations | Phenotype:Defects in neural and cardiac development; embryonic lethality | [552652] | |||
| References | |||||
| Ref 552652 | Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6186-93. | ||||
| Ref 552975 | Breast cancer cells can switch between estrogen receptor alpha and ErbB signaling and combined treatment against both signaling pathways postpones development of resistance. Breast Cancer Res Treat. 2010 Jun;121(3):601-13. doi: 10.1007/s10549-009-0506-y. Epub 2009 Aug 21. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.